VivoSense is excited to announce a collaboration with Cambridge Cognition to capture measures of cognitive and physical function using digital health tools. Both organizations are united in their interests to develop low-burden and patient-centric digital clinical outcome measures that more comprehensively and holistically capture how individuals function in real-world environments.
VivoSense recently launched the MEADOW-AD study (Meaningful Ecological Assessments Derived from Wearables in Alzheimer’s Disease), which aims to develop and validate real-world measures of physical function in patients with Alzheimer’s disease captured passively via wearable sensors.
Walking is a central component of mobility and functional independence; the MEADOW-AD study will focus on developing machine learning methods to measure aspects of walking behavior with wearable sensors in patients with Alzheimer’s disease.
Wearable sensors provide an opportunity to assess how patients function in their home environments with low burden and ultimately improve the study, treatment, and care for vulnerable populations at risk of losing independence. The MEADOW-AD study will generate the foundational evidence needed to develop validated clinical outcome measures that will be accepted as efficacy endpoints in future clinical trials of Alzheimer’s disease.
Cambridge Cognition will supply touchscreen cognitive assessments that will provide active metrics of cognitive performance, such as sensitive measures of memory impairment. These measures can then be analyzed in conjunction with passive data collected from wearable technology. Together, these data will provide a more holistic understanding of the physical and mental changes associated with Alzheimer’s disease and how these changes affect an individual’s day-to-day life.
This study is a valuable first step to creating a more comprehensive understanding of cognitive impairments in older populations by using the synergy of both active and passive digital technologies that can be deployed remotely to facilitate patient-centric digital clinical outcome measures.
The MEADOW-AD study is partly funded by a grant from the National Institutes of Health. It is being conducted at the Center for Human Health and Performance at the University of Massachusetts.
About Cambridge Cognition
Cambridge Cognition is a leading technology company optimizing the assessment of cognition for better brain health with scientifically validated digital health solutions.
Their software enables gold-standard research and efficient clinical trials, accelerating safe and effective treatment development and helping to improve patient outcomes in conditions affecting brain health. For over 30 years, their technology has been at the forefront of scientific discovery, delivering value to research institutions, healthcare providers and pharmaceutical and biotechnology companies worldwide. From digital health tools to mobile applications for drug development, they provide interactive and innovative digital cognitive assessment technologies that capture meaningful, reliable data anytime, anywhere.